Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Portola Pharmaceuticals)"
Count: 29
Selected: 0
| NCT ID | Title |
|---|
| NCT03346083 | Study Evaluating PK/PD and Safety of Betrixaban in Pediatric Patients | ||
| NCT03330457 | A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing | ||
| NCT03218241 | Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote | ||
| NCT03083704 | A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa | ||
| NCT02596100 | A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations | ||
| NCT02207725 | A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban | ||
| NCT01765868 | A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers | ||
| NCT01765855 | An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects | ||
| NCT01758432 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4) | ||
| NCT01583218 | Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) | ||
| NCT01229254 | Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter | ||
| NCT00999336 | A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment | ||
| NCT00984113 | Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment | ||
| NCT00751231 | A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI | ||
| NCT00742859 | Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin | ||
| NCT00546260 | Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI | ||
| NCT00375609 | Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT) | ||
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | ||
| NCT03613402 | BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes | ||
| NCT03578146 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4) | ||
| NCT03551743 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4) | ||
| NCT03551730 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4) | ||
| NCT03397888 | The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist | ||
| NCT03310021 | A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects | ||
| NCT02220725 | A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban | ||
| NCT03728166 | Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT) | ||
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | ||
| NCT02329327 | A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study) | ||
| NCT02745054 | Safety of Oral Anticoagulants Registry |
